Physicians' Academy for Cardiovascular Education
Recent CVOTs with GLP-1RAs included kidney outcomes as a secondary endpoint. Johannes Mann presents kidney results of these trials and raises questions from a nephrologist's perspective.
ERA-EDTA 2020 An analysis of pooled data from CVOT trials that evaluated semaglutide showed that semaglutide slowed down decline of eGFR compared to placebo.
The largest cardiology congress ESC was just announced to turn fully digital. PACE-CME is committed to help sharing the news and deliver our cardiovascular education
Treatment with liraglutide plus lifestyle therapy led to a greater reduction in BMI standard-deviation score than placebo plus lifestyle therapy in adolescents with obesity.
Prof. Verma shares the data of subanalyses of the LEADER and SUSTAIN-6 trials on the effect of GLP-1RA treatment in T2DM patients with peripheral artery disease.
This e-learning course focusses on the effect of GLP-1RAs on kidney outcomes in diabetes patients. Member registration (free) is needed to enroll in this course.
A meta-analysis of GLP-1RA outcome trials show that treatment reduces the risk of CV and kidney events in T2DM. Subgroup analyses did not explain previously observed differences in trial results.
Prof. Knop gives an overview of potential mechanisms of action of GLP-1RAs to explain observed effects on glycemia, body weight, blood pressure and blood lipids.
Prof. Sattar shows that CV risk is heterogenous in patients with diabetes, and explains why new diabetes drugs, such as GLP-1RAs, are recommended for patients with diabetes and CV risk.
The US FDA has approved semaglutide tablets as an adjunct to diet and exercise to improve glycemic control in adults with T2DM.
ESC 2019 As chair of the guidelines task force, prof. Cosentino discusses the most important changes in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD, based on new evidence from CV outcomes trials.
The PIONEER 2 and 8 studies evaluated HbA1c reduction and weight reduction with oral semaglutide against empagliflozin in T2DM patients on metformin and against placebo on an insulin-background.
